Fulgent Genetics
FLGT
20.57
-0.01
-0.05%
Fulgent Genetics
US · FLGT
#3667 by market cap
Listed 2016
20.57
-0.01
-0.05%
Live - 5344 symbols - heartbeat 289s ago
· 2026-10-07 19:54
After-hours
20.57
0.00%
- Market cap
- 565.99M
- P/E (TTM)i
- -7.27
- P/Bi
- 0.57
- EPSi
- -1.97
- Div yieldi
- 0.00%
- 52W posi
- 40%
Reader sentiment
Are you bullish or bearish on FLGT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.27, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +13.83% YoY
Margins
- Gross margin
- 40.56%
- Operating margin
- -28.23%
- Net margin
- -18.75%
Key ratios & quality
- Enterprise valuei
- 233.81M
- Altman Z-Scorei
- 4.27
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21.35M | 32.53M | 421.71M | 992.58M | 618.97M | 289.21M | 283.47M | 322.67M |
| Gross profit | 10.65M | 18.42M | 331.91M | 777.05M | 366.90M | 104.46M | 107.22M | 130.88M |
| Selling & admin expenses | 10.19M | 12.31M | 30.17M | 75.17M | 149.99M | 130.47M | 124.35M | 160.04M |
| Research & development | 5.53M | 6.54M | 11.58M | 24.22M | 28.91M | 41.44M | 48.82M | 53.91M |
| Operating profit | -5.07M | -428.00K | 290.16M | 675.95M | 181.50M | -75.30M | -73.92M | -91.10M |
| Pretax profit | -4.64M | 409.00K | 291.68M | 677.30M | 184.03M | -174.09M | -51.96M | -70.03M |
| Tax | 36.00K | 43.00K | 72.53M | 174.80M | 42.10M | 1.15M | -8.14M | -8.39M |
| Net profit | -5.61M | -411.00K | 214.31M | 506.24M | 141.92M | -175.24M | -43.82M | -61.63M |
| Basic EPS | 0 | 0 | 9 | 17 | 5 | -6 | -1 | -2 |
| Diluted EPS | -0.31 | -0.02 | 8.91 | 16.38 | 4.63 | -5.63 | -1.41 | -1.97 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 73.46M | 81.80M | 84.07M | 83.34M | 71.14M | 85.39M |
| Gross profit | 28.35M | 34.44M | 35.51M | 32.58M | 21.49M | 25.68M |
| Selling & admin expenses | 33.76M | 38.68M | 34.98M | 52.62M | 39.91M | 42.42M |
| Research & development | 12.40M | 13.48M | 13.86M | 14.17M | 14.18M | 14.55M |
| Operating profit | -19.80M | -19.71M | -15.35M | -36.24M | -34.62M | -33.90M |
| Pretax profit | -11.72M | -21.52M | -7.51M | -29.27M | -25.98M | -29.69M |
| Tax | 176.00K | -2.26M | -683.00K | -5.62M | -704.00K | 29.00K |
| Net profit | -11.90M | -19.26M | -6.83M | -23.65M | -25.27M | -29.72M |
| Basic EPS | 0 | -1 | 0 | -1 | -1 | -1 |
| Diluted EPS | -0.37 | -0.62 | -0.21 | -0.76 | -0.80 | -1.05 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 39.54M | 37.08M | 523.62M | 611.96M | 627.87M | 507.85M | 353.57M | 550.49M |
| Cash & ST investments | 31.03M | 28.27M | 299.37M | 450.50M | 526.24M | 424.15M | 258.11M | 336.08M |
| Inventory | 314.00K | 277.00K | 16.49M | 12.21M | 4.28M | 5.83M | 8.38M | 10.60M |
| Total assets | 53.90M | 88.76M | 700.46M | 1.28B | 1.39B | 1.24B | 1.22B | 1.21B |
| Total current liabilities | 2.74M | 3.72M | 130.12M | 105.31M | 88.11M | 73.02M | 72.90M | 84.97M |
| Short-term debt | -- | 420.00K | 15.02M | 21.28M | 26.77M | 5.14M | 1.86M | 1.94M |
| Long-term debt | -- | -- | -- | -- | 3.37M | 2.96M | 2.49M | 1.96M |
| Total liabilities | 2,752,000.00 | 5,979,000.00 | 131,074,000.00 | 112,840,000.00 | 116,178,000.00 | 102,042,000.00 | 90,805,000.00 | 106,810,000.00 |
| Total equity | 51.15M | 82.78M | 569.39M | 1.17B | 1.27B | 1.13B | 1.13B | 1.11B |
| Retained earnings | -63.02M | -63.43M | 150.88M | 657.60M | 801.00M | 633.18M | 590.47M | 529.95M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 416.78M | 428.73M | 507.37M | 550.49M | 479.04M | 454.77M |
| Cash & ST investments | 320.32M | 292.93M | 375.80M | 336.08M | 276.30M | 257.03M |
| Inventory | 8.62M | 8.98M | 10.06M | 10.60M | 12.06M | 11.67M |
| Total assets | 1.21B | 1.20B | 1.21B | 1.21B | 1.16B | 1.09B |
| Total current liabilities | 65.92M | 71.34M | 72.43M | 84.97M | 90.13M | 71.76M |
| Short-term debt | 1.81M | 1.66M | 1.96M | 1.94M | 2.41M | 2.34M |
| Long-term debt | 1.96M | 1.96M | 1.96M | 1.96M | 1.48M | 1.48M |
| Total liabilities | 82,974,000.00 | 88,202,000.00 | 93,806,000.00 | 106,810,000.00 | 112,215,000.00 | 93,237,000.00 |
| Total equity | 1.12B | 1.11B | 1.12B | 1.11B | 1.04B | 995.99M |
| Retained earnings | 578.94M | 559.98M | 553.37M | 529.95M | 505.13M | 475.60M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -675.00K | 5.52M | 140.63M | 538.58M | 253.52M | 27.00M | 21.06M | -101.64M |
| Depreciation & amortization | 2.16M | 2.11M | 2.96M | 11.00M | 32.66M | 26.14M | 24.93M | 24.12M |
| Free cash flow | -3.51M | 4.34M | 105.50M | 514.73M | 234.75M | 4.80M | -19.26M | -124.21M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 28.74M | 246.13M | 85.32M | -76.11M | -27.79M | -3.12M | -13.92M |
| Ending cash balance | 6.74M | 11.97M | 87.43M | 164.89M | 79.51M | 97.47M | 55.28M | 50.33M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -4.43M | -30.17M | 11.11M | -78.14M | 7.10M | -23.76M |
| Depreciation & amortization | 5.92M | 6.05M | 6.04M | 6.11M | 6.00M | 7.68M |
| Free cash flow | -9.15M | -37.00M | 5.06M | -83.12M | 1.90M | -27.62M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -10.57M | -2.55M | -357.00K | -447.00K | -44.28M | -24.14M |
| Ending cash balance | 67.42M | 88.02M | 117.78M | 50.33M | 23.53M | 26.44M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -10.65 | -0.61 | 65.72 | 58.72 | 11.82 | -13.97 | -3.76 | -5.39 |
| ROA %i | -10.09 | -0.58 | 54.31 | 51.27 | 10.76 | -12.80 | -3.48 | -4.97 |
| ROIC %i | -11.25 | -1.67 | 63.57 | 57.39 | 11.28 | -15.09 | -6.03 | -7.75 |
| 5-year avg ROE %i | -- | -- | 0.80 | 21.71 | 25.00 | 24.34 | 23.71 | 9.48 |
| EBIT margin %i | -23.75 | -1.32 | 68.80 | 68.10 | 29.32 | -26.03 | -26.08 | -21.68 |
| FCF / sales %i | -- | 12.91 | 24.69 | 51.86 | 37.93 | 1.66 | -- | -- |
| Current ratioi | 14.44 | 9.96 | 4.02 | 5.81 | 7.13 | 6.96 | 4.85 | 6.48 |
| Quick ratioi | 13.67 | 9.53 | 3.87 | 5.64 | 6.83 | 6.60 | 4.60 | 5.03 |
| Debt / assetsi | 0.00 | 3.02 | 2.14 | 1.66 | 2.81 | 1.23 | 0.69 | 0.63 |
| LT debt / equityi | -- | 2.73 | -- | -- | 0.96 | 0.89 | 0.58 | 0.52 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -932.67 |
| Revenue CAGR (3Y) %i | 30.64 | 21.19 | 182.37 | 259.57 | 166.97 | -11.81 | -34.15 | -19.52 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | 91.53 | -- | -- | 278.33 | -64.31 | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -3.61 | -4.54 | -3.80 | -5.39 | -6.78 | -7.97 |
| ROA %i | -3.35 | -4.20 | -3.51 | -4.97 | -6.25 | -7.37 |
| ROIC %i | -5.95 | -6.97 | -6.31 | -7.75 | -9.28 | -10.48 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -21.83 | -21.91 | -18.01 | -21.68 | -26.28 | -28.50 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.32 | 6.01 | 7.01 | 6.48 | 5.31 | 6.34 |
| Quick ratioi | 6.08 | 5.30 | 6.28 | 5.03 | 3.91 | 4.56 |
| Debt / assetsi | 0.64 | 0.62 | 0.62 | 0.63 | 0.86 | 0.87 |
| LT debt / equityi | 0.52 | 0.51 | 0.50 | 0.52 | 0.71 | 0.71 |
| Interest coveragei | -- | -- | -- | -932.67 | -1,079.51 | -769.43 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Laboratory services is the largest reported line at 99.96% of revenue, across 2 reported segments.
- The next-largest line, Therapeutic Development, is a distant second at 0.04% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Laboratory services99.96%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.